TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32660350

Group type: EXPERIMENTAL
Intervention: High status condition
Number of subjects: 6426

Group type: COMPARATOR
Intervention: Low status condition
Number of subjects: 6426

Group type: EXPERIMENTAL
Intervention: Upper-class individuals
Number of subjects: 6426

Group type: COMPARATOR
Intervention: Working-class individuals
Number of subjects: 6426
Study: 36096430

Group type: EXPERIMENTAL
Intervention: SpikoGen® vaccine
Number of subjects: 16876

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16876
Study: 33840531

Group type: EXPERIMENTAL
Intervention: LED-mediated photobiomodulation (850 nm wavelength, 60 mW/cm2 power, continuous LED for 5 min/d)
Number of subjects: 20

Group type: COMPARATOR
Intervention: No photobiomodulation (control side)
Number of subjects: 20
Study: 35574009

Group type: EXPERIMENTAL
Intervention: Insulin aspart injected with a needle-free syringe into the abdomen
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Insulin aspart injected with a needle-free syringe into the upper arm
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Insulin aspart injected with a needle-free syringe into the thigh
Number of subjects: 8
Study: 32238335

Group type: EXPERIMENTAL
Intervention: One-way text messages
Number of subjects: 705

Group type: COMPARATOR
Intervention: No text messages (Control)
Number of subjects: 705
Study: 34082633

Group type: EXPERIMENTAL
Intervention: Higher levels of instrumental support seeking
Number of subjects: 564

Group type: EXPERIMENTAL
Intervention: Lower levels of proactive coping
Number of subjects: 564

Group type: EXPERIMENTAL
Intervention: Lower levels of emotional support seeking
Number of subjects: 564

Group type: EXPERIMENTAL
Intervention: Demographic factors (drug-use-related disorders)
Number of subjects: 564

Group type: EXPERIMENTAL
Intervention: Demographic factors (unemployment)
Number of subjects: 564

Group type: EXPERIMENTAL
Intervention: Demographic factors (younger age)
Number of subjects: 564
Study: 32979230

Group type: EXPERIMENTAL
Intervention: 12-week guided self-help
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 16-week guided self-help
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 16-week pure self-help
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 12-week guided self-help with access to a discussion forum
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 12-week guided self-help without access to a discussion forum
Number of subjects: 0

Group type: COMPARATOR
Intervention: Waitlist control condition
Number of subjects: 0
Study: 36434514

Group type: EXPERIMENTAL
Intervention: ZYN002 (cannabidiol transdermal gel) 250 mg or 500 mg daily for 12 weeks
Number of subjects: 212

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 212
Study: 34651093

Group type: EXPERIMENTAL
Intervention: Volar locking plate
Number of subjects: 120

Group type: COMPARATOR
Intervention: Dorsal locking nail-plate
Number of subjects: 120

Group type: COMPARATOR
Intervention: Volar locking plate and Dorsal locking nail-plate
Number of subjects: 120
Study: 32583085

Group type: EXPERIMENTAL
Intervention: Convolutional Neural Network (CNN) for semantic image segmentation
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Convolutional Neural Network (CNN) on BrainWeb data set
Number of subjects: 43

Group type: COMPARATOR
Intervention: Classical FAST algorithm on BrainWeb data set
Number of subjects: 43
Study: 36160788

Group type: EXPERIMENTAL
Intervention: Peyton’s Four‐Step Approach
Number of subjects: 186

Group type: COMPARATOR
Intervention: Standard bedside teaching (Control)
Number of subjects: 186
Study: 32251729

Group type: EXPERIMENTAL
Intervention: Colchicine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study: 35050705

Group type: EXPERIMENTAL
Intervention: App-based visual-acoustic biofeedback using Speech Therapist's App for /r/ Treatment
Number of subjects: 4

Group type: COMPARATOR
Intervention: Nonbiofeedback treatment using Speech Therapist's App for /r/ Treatment
Number of subjects: 4
Study: 36205492

Group type: EXPERIMENTAL
Intervention: Uncertainty Communication Education Module (training in communication skills)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Delayed access (no intervention at T2)
Number of subjects: 109
Study: 33191408

Group type: EXPERIMENTAL
Intervention: Belotecan (0.5 mg/m2)
Number of subjects: 164

Group type: COMPARATOR
Intervention: Topotecan (1.5 mg/m2)
Number of subjects: 164
Study: 35820814

Group type: EXPERIMENTAL
Intervention: Combined physiological recruitment maneuver (CPRM) with sigh in lateral position
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group (C-group)
Number of subjects: 70
Study: 33662163

Group type: EXPERIMENTAL
Intervention: real-tDCS (right anodal/left cathodal)
Number of subjects: 17

Group type: COMPARATOR
Intervention: sham-tDCS
Number of subjects: 17
Study: 32820015

Group type: EXPERIMENTAL
Intervention: Entospletinib + 7+3 (cytarabine + daunorubicin)
Number of subjects: 53
Study: 34441026

Group type: EXPERIMENTAL
Intervention: Complete dentures with vitamin B12
Number of subjects: 252

Group type: COMPARATOR
Intervention: Conventional complete dentures
Number of subjects: 252
Study: 33203854

Group type: EXPERIMENTAL
Intervention: Trastuzumab (T; N = 34)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Lapatinib (L; N = 36)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Both trastuzumab and lapatinib (TL; N = 58)
Number of subjects: 128
Study: 32803294

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine inhalation therapy (2400 mg daily for 8 weeks)
Number of subjects: 120
Study: 34461811

Group type: EXPERIMENTAL
Intervention: DNA methylation sites and genes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Causal pathways in the brain
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Causal pathways in the blood
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: DNA methylation influence on gene expression
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Regulation of gene expression
Number of subjects: 0
Study: 32899129

Group type: EXPERIMENTAL
Intervention: Prolonged-release protein substitute
Number of subjects: 13
Study: 35654284

Group type: EXPERIMENTAL
Intervention: Individual intervention
Number of subjects: 210

Group type: COMPARATOR
Intervention: Group intervention
Number of subjects: 210
Study: 34697956

Group type: EXPERIMENTAL
Intervention: Video group (34 patients)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Handout group (37 patients)
Number of subjects: 89
Study: 33656762

Group type: EXPERIMENTAL
Intervention: Prediction model for in-hospital death
Number of subjects: 31157

Group type: EXPERIMENTAL
Intervention: Prediction model for chronic lung disease
Number of subjects: 31157

Group type: EXPERIMENTAL
Intervention: Prediction model for intraventricular hemorrhage (grade III or IV)
Number of subjects: 31157

Group type: EXPERIMENTAL
Intervention: Prediction model for periventricular leukomalacia
Number of subjects: 31157

Group type: EXPERIMENTAL
Intervention: Prediction model for cerebral palsy at 3 years of age
Number of subjects: 31157

Group type: EXPERIMENTAL
Intervention: Prediction model for developmental quotient of <70 at 3 years of age
Number of subjects: 31157
Study: 32800493

Group type: EXPERIMENTAL
Intervention: Granulocyte Colony-Stimulating Factor (G-CSF)
Number of subjects: 1493

Group type: EXPERIMENTAL
Intervention: Epoetin alfa (EPO)
Number of subjects: 1493

Group type: COMPARATOR
Intervention: 6 × 5-fluorouracil, epirubicin, and cyclophosphamide (FEC120)
Number of subjects: 1493

Group type: COMPARATOR
Intervention: 4 × epirubicin and cyclophosphamide followed by 4 × docetaxel (EC-DOC)
Number of subjects: 1493

Group type: EXPERIMENTAL
Intervention: Baseline fatigue level
Number of subjects: 1493
Study: 36201995

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) for GAD
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Behavioral strengths
Number of subjects: 137
Study: 34325680

Group type: EXPERIMENTAL
Intervention: Severe anaemia (Hb 4-6 g/dL and no severity features), no transfusion during initial admission
Number of subjects: 3894

Group type: EXPERIMENTAL
Intervention: HIV infection
Number of subjects: 3894

Group type: EXPERIMENTAL
Intervention: ≥2 hospital admissions in the preceding 12 months
Number of subjects: 3894

Group type: EXPERIMENTAL
Intervention: History of transfusion
Number of subjects: 3894

Group type: EXPERIMENTAL
Intervention: Missing ≥1 trial medication dose
Number of subjects: 3894

Group type: EXPERIMENTAL
Intervention: Malaria (among children with no prior history of transfusion)
Number of subjects: 3894

Group type: EXPERIMENTAL
Intervention: Younger age
Number of subjects: 3894

Group type: EXPERIMENTAL
Intervention: Known sickle cell disease
Number of subjects: 3894

Group type: EXPERIMENTAL
Intervention: Gross splenomegaly
Number of subjects: 3894

Group type: EXPERIMENTAL
Intervention: Enlarged spleen
Number of subjects: 3894
Study: 35311593

Group type: EXPERIMENTAL
Intervention: 500 mg shrimp oil once per day for eight weeks
Number of subjects: 64

Group type: COMPARATOR
Intervention: Identical placebo containing medium-chain triglycerides
Number of subjects: 64
Study: 35387677

Group type: EXPERIMENTAL
Intervention: Iscador M
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Iscador P
Number of subjects: 45

Group type: COMPARATOR
Intervention: Physiological saline (placebo)
Number of subjects: 45
Study: 35598698

Group type: EXPERIMENTAL
Intervention: Calorie restriction (CR)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Eating interval
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: First meal timing variation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Regular first meal timing
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Last meal timing
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Time to 50% daily calorie intake
Number of subjects: 0
Study: 34941541

Group type: EXPERIMENTAL
Intervention: iSMI GET.ON Stress (7 sessions + 1 booster session, no therapeutic guidance)
Number of subjects: 396

Group type: COMPARATOR
Intervention: Waiting list control group (6-month waiting period)
Number of subjects: 396

Group type: EXPERIMENTAL
Intervention: iSMI GET.ON Stress
Number of subjects: 396
Study: 34965763

Group type: EXPERIMENTAL
Intervention: Needle-pilot US-guided technique
Number of subjects: 51

Group type: COMPARATOR
Intervention: Standard US guidance
Number of subjects: 51
Study: 33713215

Group type: EXPERIMENTAL
Intervention: Trifluridine/tipiracil (FTD/TPI)
Number of subjects: 145

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 145
Study: 34624248

Group type: EXPERIMENTAL
Intervention: 1 month followed by 2-month placebo (Group A)
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: 2 months followed by 1-month placebo (Group B)
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: 3 months (Group C)
Number of subjects: 252

Group type: COMPARATOR
Intervention: All groups
Number of subjects: 252
Study: 33423209

Group type: COMPARATOR
Intervention: Caries experience-free children
Number of subjects: 3702

Group type: COMPARATOR
Intervention: Initial caries lesions (ICDAS1-2)
Number of subjects: 3702

Group type: COMPARATOR
Intervention: Mean d1-2t/D1-2T
Number of subjects: 3702

Group type: COMPARATOR
Intervention: Mean d3-6mft/D3-6MFT
Number of subjects: 3702

Group type: COMPARATOR
Intervention: Caries experience related to socio-demographic factors
Number of subjects: 3702

Group type: COMPARATOR
Intervention: Initial caries lesions probability
Number of subjects: 3702

Group type: COMPARATOR
Intervention: Caries prevalence and experience levels over ten years
Number of subjects: 3702
Study: 34935707

Group type: EXPERIMENTAL
Intervention: Exercise Training (ET)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 38
Study: 33188696

Group type: EXPERIMENTAL
Intervention: Positive illness perceptions
Number of subjects: 1087

Group type: EXPERIMENTAL
Intervention: Improvers (switched from negative to positive illness perceptions)
Number of subjects: 1087

Group type: COMPARATOR
Intervention: Negative illness perceptions
Number of subjects: 1087
Study: 34826525

Group type: EXPERIMENTAL
Intervention: Dynamic descriptive social norm message displayed during the first two weeks of the study period
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Dynamic descriptive social norm message displayed during the last two weeks of the study period
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: High fidelity stores with the intervention
Number of subjects: 22
Study: 32788318

Group type: EXPERIMENTAL
Intervention: 2-handed C-E technique
Number of subjects: 74

Group type: COMPARATOR
Intervention: 2-handed V-E technique
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 74
Study: 34952104

Group type: EXPERIMENTAL
Intervention: Sources of Strength program (intervention group)
Number of subjects: 1633

Group type: COMPARATOR
Intervention: Wait-list control condition (control group)
Number of subjects: 1633
Study: 37584047

Group type: EXPERIMENTAL
Intervention: Early structured mobilisation protocol within 3 days of hospital admission till discharge
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (usual medical care only)
Number of subjects: 30
Study: 32919068

Group type: EXPERIMENTAL
Intervention: High-dose eplerenone (100-200 mg)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study: 32664953

Group type: EXPERIMENTAL
Intervention: Withholding enteral feeds for 12 hours from the start of transfusion
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Continuing enteral feeds during transfusion
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Restriction of enteral feed volume to 120 ml/kg/day for 12 hours
Number of subjects: 41

Group type: COMPARATOR
Intervention: All groups combined
Number of subjects: 41
Study: 35918311

Group type: EXPERIMENTAL
Intervention: 0.5 g of dried psilocybin mushrooms
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 32233985

Group type: EXPERIMENTAL
Intervention: Pretarsal Group: 5 units of onabotulinum toxin A injected into 2 points of the pretarsal portion
Number of subjects: 30

Group type: COMPARATOR
Intervention: Preseptal Group: 5 units of onabotulinum toxin A injected into 4 points of the preseptal portion
Number of subjects: 30
Study: 32176761

Group type: EXPERIMENTAL
Intervention: Standard sausage rich in animal fat (mortadella)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Modified product based on a plant-derived fat analogue and an aroma
Number of subjects: 8
Study: 616564354

Group type: EXPERIMENTAL
Intervention: 50%LBY
Number of subjects: 16

Group type: COMPARATOR
Intervention: 0:0:100 (RS)
Number of subjects: 16

Group type: COMPARATOR
Intervention: 0:70:30 (0%LBY)
Number of subjects: 16

Group type: COMPARATOR
Intervention: 20:50:30 (20%LBY)
Number of subjects: 16

Group type: COMPARATOR
Intervention: 50:20:30 (50%LBY)
Number of subjects: 16
Study: 35998623

Group type: EXPERIMENTAL
Intervention: SOBERANA 02 (two doses) + SOBERANA Plus (third dose)
Number of subjects: 810

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 810
Study: 34310011

Group type: EXPERIMENTAL
Intervention: ORMD-0801 (16 or 24 mg, once daily at bedtime for 28 days)
Number of subjects: 188

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 188
Study: 33655801

Group type: EXPERIMENTAL
Intervention: Enrollment in the trial (n=40)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Declined enrollment (n=50)
Number of subjects: 90
Study: 34189703

Group type: EXPERIMENTAL
Intervention: GSK2586881 0.8 mg/kg
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 34783100

Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids (ICS) prescribed if blood eosinophils ≥3%
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Targeted antibiotics for airway bacterial infection
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 60
Study: 33150711

Group type: EXPERIMENTAL
Intervention: Needle acupuncture
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Laser acupuncture
Number of subjects: 180

Group type: COMPARATOR
Intervention: Placebo laser acupuncture
Number of subjects: 180
Study: 34767488

Group type: EXPERIMENTAL
Intervention: Independently getting off the floor (IGO) technique
Number of subjects: 17
Study: 32049923

Group type: EXPERIMENTAL
Intervention: 0.005% estriol vaginal gel
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study: 34043000

Group type: EXPERIMENTAL
Intervention: Low-fat vegan diet
Number of subjects: 223
Study: 32894700

Group type: EXPERIMENTAL
Intervention: Fat tissue grafts (group A)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Areolar tissue grafts (group B)
Number of subjects: 140
Study: 33982797

Group type: EXPERIMENTAL
Intervention: Nitrate-containing beetroot juice
Number of subjects: 93

Group type: COMPARATOR
Intervention: Doxazosin
Number of subjects: 93

Group type: COMPARATOR
Intervention: Spironolactone
Number of subjects: 93

Group type: COMPARATOR
Intervention: Placebo nitrate-depleted juice
Number of subjects: 93
Study: 32929822

Group type: EXPERIMENTAL
Intervention: Pharmacist-led, patient-oriented education and medication management intervention
Number of subjects: 116

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 116
Study: 35335942

Group type: EXPERIMENTAL
Intervention: Jet Nebulizer with Valved Holding Chamber (JN + VHC)
Number of subjects: 7
Study: 32014275

Group type: EXPERIMENTAL
Intervention: Salvage surgery (n=78 out of 91 willing patients)
Number of subjects: 113

Group type: COMPARATOR
Intervention: No salvage surgery (n=22 unwilling patients)
Number of subjects: 113
Study: 34793586

Group type: EXPERIMENTAL
Intervention: Freshest available blood (mean age of blood units: 11 days)
Number of subjects: 14461

Group type: COMPARATOR
Intervention: Oldest available blood (mean age of blood units: 23 days)
Number of subjects: 14461

Group type: EXPERIMENTAL
Intervention: Blood age as a continuous variable (duration of storage in days)
Number of subjects: 14461
Study: 34881943

Group type: EXPERIMENTAL
Intervention: Duchenne smile
Number of subjects: 231

Group type: EXPERIMENTAL
Intervention: Grimace
Number of subjects: 231

Group type: COMPARATOR
Intervention: Neutral expression
Number of subjects: 231
Study: 35453122

Group type: EXPERIMENTAL
Intervention: Multitask Training (MTT)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Multicomponent Training (MCT)
Number of subjects: 42
Study: 33849913

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (2,000 IU orally daily for 1 year)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300
Study: 35680252

Group type: EXPERIMENTAL
Intervention: Cannabis products added to a behavioural pain management and prescription opioid taper support programme
Number of subjects: 250

Group type: COMPARATOR
Intervention: Abstinence from cannabis use
Number of subjects: 250
Study: 36395262

Group type: EXPERIMENTAL
Intervention: 1.5% potassium oxalate (GPO) for 10 min
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo gel (GP)
Number of subjects: 50
Study: 33218539

Group type: EXPERIMENTAL
Intervention: PTSD group
Number of subjects: 18
Study: 36252745

Group type: EXPERIMENTAL
Intervention: Duloxetine (60 mg daily from the day of surgery to postoperative day 6)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study: 34404842

Group type: EXPERIMENTAL
Intervention: Negative pressure wound therapy (NPWT)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Standard care (silver‐impregnated dressings)
Number of subjects: 101
Study: 32100500

Group type: EXPERIMENTAL
Intervention: Wheat-grain moxibustion at Yinbai (SP 1), performed once a day with an interval of 1 day between two 3-day treatments.
Number of subjects: 54

Group type: COMPARATOR
Intervention: Oral administration of dydrogesterone tablet, 10 mg twice a day.
Number of subjects: 54
Study: 35180298

Group type: EXPERIMENTAL
Intervention: Acetaminophen (500mg or 1000mg 6-hourly for 72 hours)
Number of subjects: 396

Group type: COMPARATOR
Intervention: No acetaminophen (Control)
Number of subjects: 396
Study: 35569002

Group type: EXPERIMENTAL
Intervention: Oral Misoprostol (OM) 50 µg four hourly for 48 hours
Number of subjects: 144

Group type: COMPARATOR
Intervention: Supra cervical Foley catheter for 48 hours
Number of subjects: 144
Study: 35063969

Group type: EXPERIMENTAL
Intervention: Canagliflozin
Number of subjects: 4401

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4401

Group type: COMPARATOR
Intervention: Recalculation using the 2009 CKD-EPI equation without race-specific coefficient
Number of subjects: 4401

Group type: COMPARATOR
Intervention: Recalculation using the 2021 CKD-EPI equation
Number of subjects: 4401

Group type: COMPARATOR
Intervention: Recalculation using the 2009 equation
Number of subjects: 4401

Group type: COMPARATOR
Intervention: Recalculation using the 2021 equation
Number of subjects: 4401
Study: 34114522

Group type: EXPERIMENTAL
Intervention: Valsalva manoeuvre (VM)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Tenaculum
Number of subjects: 107
Study: 32871329

Group type: EXPERIMENTAL
Intervention: Immediate complete revascularization
Number of subjects: 840

Group type: COMPARATOR
Intervention: Staged complete revascularization (within 19-45 days)
Number of subjects: 840
Study: 34756180

Group type: EXPERIMENTAL
Intervention: Temocillin
Number of subjects: 152

Group type: COMPARATOR
Intervention: Cefotaxime
Number of subjects: 152
Study: 33588938

Group type: EXPERIMENTAL
Intervention: Multi-Round Delphi
Number of subjects: 180

Group type: COMPARATOR
Intervention: Real-Time Delphi
Number of subjects: 180
Study: 32843372

Group type: EXPERIMENTAL
Intervention: Theranova 400 dialyzer
Number of subjects: 172

Group type: COMPARATOR
Intervention: Elisio‐17H dialyzer
Number of subjects: 172
Study: 36231179

Group type: EXPERIMENTAL
Intervention: Positive expectations (SE+, OE+)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Self-Efficacy positive (SE+)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Outcome Expectations positive (OE+)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Perceived Fatigue
Number of subjects: 75
Study: 34052421

Group type: COMPARATOR
Intervention: Ultrasonic scaling + oral hygiene instructions
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Ultrasonic scaling/oral hygiene instructions + aPDT
Number of subjects: 40
Study: 32558469

Group type: EXPERIMENTAL
Intervention: Systematic treatment with rifampin, isoniazid, ethambutol, and pyrazinamide daily for 2 months, followed by rifampin and isoniazid daily for 4 months.
Number of subjects: 1047

Group type: COMPARATOR
Intervention: Guided treatment (screening with Xpert MTB/RIF test, urinary lipoarabinomannan test, and chest radiography).
Number of subjects: 1047

Group type: EXPERIMENTAL
Intervention: Systematic treatment
Number of subjects: 1047

Group type: COMPARATOR
Intervention: Guided treatment
Number of subjects: 1047